{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:14:55Z","timestamp":1788243295224,"version":"build-2803163510"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This single-center prospective observational cohort study aimed to investigate the prognostic value of combined low-density lipoprotein cholesterol (LDL-C) and remnant cholesterol (RC) stratification in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 812 STEMI patients were enrolled and stratified into four groups according to LDL-C and RC levels measured at 1-month post-PCI. The primary endpoint was 24-month major adverse cardiovascular events (MACE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The overall MACE rate increased stepwise across the four subgroups (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001). Multivariate Cox regression showed that elevated RC was independently associated with MACE (HR\u2009=\u20091.559, 95% CI: 1.018\u22122.386,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.041), whereas isolated high LDL-C was not (HR\u2009=\u20091.329, 95% CI: 0.992\u22121.781,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.057). Compared with the low LDL-C\u2009+\u2009low RC group, the high LDL-C\u2009+\u2009high RC group carried the highest MACE risk (HR\u2009=\u20092.535, 95% CI: 1.591\u20134.041,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001), followed by the low LDL-C\u2009+\u2009high RC group (HR\u2009=\u20091.874, 95% CI: 1.153\u20133.045,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.011).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Combined LDL-C and RC stratification may assist risk evaluation in STEMI patients after primary PCI. Elevated RC, rather than isolated high LDL-C, is associated with adverse outcomes, which may help identify patients with residual lipid-related risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1901661","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:33:27Z","timestamp":1788240807000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of combined LDL-C and remnant cholesterol stratification for 24-month major adverse cardiovascular events after primary PCI in patients with STEMI"],"prefix":"10.3389","volume":"13","author":[{"given":"Qianying","family":"Xie","sequence":"first","affiliation":[{"name":"Department of Cardiology, Tiantai People\u2019s Hospital of Zhejiang Province","place":["Taizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tiantai People\u2019s Hospital of Zhejiang Province","place":["Taizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tiantai People\u2019s Hospital of Zhejiang Province","place":["Taizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tiantai People\u2019s Hospital of Zhejiang Province","place":["Taizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjie","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tiantai People\u2019s Hospital of Zhejiang Province","place":["Taizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tiantai People\u2019s Hospital of Zhejiang Province","place":["Taizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e35687","DOI":"10.1097\/MD.0000000000035687","article-title":"Comprehensive review of ST-segment elevation myocardial infarction: understanding pathophysiology, diagnostic strategies, and current treatment approaches","volume":"102","author":"Elendu","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.amjcard.2018.01.015","article-title":"Role of ST-segment resolution in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention (from the 5-year outcomes of the EXAMINATION [evaluation of the Xience-V stent in acute myocardial infarction] trial)","volume":"121","author":"Spitaleri","year":"2018","journal-title":"Am J Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.37825\/2239-9747.1058","article-title":"Novel targets and strategies addressing residual cardiovascular risk in post-acute coronary syndromes patients","volume":"26","author":"Cancro","year":"2024","journal-title":"Transl Med UniSa"},{"key":"B4","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/eurjpc\/zwaf112","article-title":"Prognostic impact of residual inflammatory and triglyceride risk in statin-treated patients with well-controlled LDL cholesterol and atherosclerotic cardiovascular disease","volume":"33","author":"Di Muro","year":"2026","journal-title":"Eur J Prev Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/eurjpc\/zwae102","article-title":"The role of remnant cholesterol in patients with ST-segment elevation myocardial infarction","volume":"31","author":"Zhou","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1093\/eurheartj\/ehab432","article-title":"Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study","volume":"42","author":"Quispe","year":"2021","journal-title":"Eur Heart J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"593168","DOI":"10.2147\/TCRM.S593168","article-title":"A narrative review of remnant cholesterol as an independent atherogenic lipoprotein in type 2 diabetes: pathophysiology and clinical implications","volume":"22","author":"Natsir","year":"2026","journal-title":"Ther Clin Risk Manag"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1093\/eurheartj\/ehag087","article-title":"Residual lipid risk in atherosclerotic cardiovascular disease","volume":"47","author":"Nordestgaard","year":"2026","journal-title":"Eur Heart J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3760\/cma.j.cn112338-20241018-00641","article-title":"Association between remnant cholesterol and the risk of atherosclerotic cardiovascular disease in a community population in Shanghai","volume":"46","author":"Deng","year":"2025","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e035764","DOI":"10.1161\/JAHA.124.035764","article-title":"Intraindividual discordance between remnant cholesterol and low-density lipoprotein cholesterol associated with incident stroke: results from 2: national cohorts","volume":"13","author":"Cui","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1161\/STROKEAHA.124.046811","article-title":"Discordant high remnant cholesterol with LDL-C increases the risk of stroke: a Chinese prospective cohort study","volume":"55","author":"Han","year":"2024","journal-title":"Stroke"},{"key":"B12","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2147\/VHRM.S553282","article-title":"Remnant cholesterol is associated with blood pressure control in US adults with hypertension: NHANES 2007\u22122018 analysis","volume":"21","author":"Feng","year":"2025","journal-title":"Vasc Health Risk Manag"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e70084","DOI":"10.1111\/jch.70084","article-title":"Association of cumulative exposure to triglyceride and remnant cholesterol with the risk of cardiovascular disease in hypertensive patients with target LDL-C","volume":"27","author":"Guo","year":"2025","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12967-022-03448-x","article-title":"Synergistic effect of the commonest residual risk factors, remnant cholesterol, lipoprotein(a), and inflammation, on prognosis of statin-treated patients with chronic coronary syndrome","volume":"20","author":"Liu","year":"2022","journal-title":"J Transl Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/j.jacc.2022.03.384","article-title":"Elevated remnant cholesterol reclassifies risk of ischemic heart disease and myocardial infarction","volume":"79","author":"Doi","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1007\/s00125-023-06016-0","article-title":"Elevated remnant cholesterol and atherosclerotic cardiovascular disease in diabetes: a population-based prospective cohort study","volume":"66","author":"Wadstr\u00f6m","year":"2023","journal-title":"Diabetologia"},{"key":"B17","doi-asserted-by":"publisher","first-page":"272","DOI":"10.2174\/157340311799960690","article-title":"The modification of serum lipids after acute coronary syndrome and importance in clinical practice","volume":"7","author":"Balci","year":"2011","journal-title":"Curr Cardiol Rev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"984711","DOI":"10.3389\/fcvm.2022.984711","article-title":"Remnant cholesterol is associated with cardiovascular mortality","volume":"9","author":"Zhang","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1536\/ihj.24-618","article-title":"Predictive value of a nomogram model constructed on the basis of residual cholesterol in predicting major post-interventional adverse cardiovascular events in patients with acute myocardial infarction","volume":"67","author":"Yin","year":"2026","journal-title":"Int Heart J"},{"key":"B22","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3390\/jcdd9120452","article-title":"Remnant-like particle cholesterol and the risk of major adverse cardiovascular events: a systematic review and meta-analysis","volume":"9","author":"Yang","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12944-024-02156-3","article-title":"The residual risk of inflammation and remnant cholesterol in acute coronary syndrome patients on statin treatment undergoing percutaneous coronary intervention","volume":"23","author":"Liao","year":"2024","journal-title":"Lipids Health Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/joim.13059","article-title":"Contribution of remnant cholesterol to cardiovascular risk","volume":"288","author":"Langsted","year":"2020","journal-title":"J Intern Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"197","DOI":"10.18773\/austprescr.2024.050","article-title":"Icosapent ethyl for reduction in cardiovascular disease risk in adults with hypertriglyceridaemia","volume":"47","year":"2024","journal-title":"Aust Prescr"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1016\/j.jacc.2020.10.008","article-title":"Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease","volume":"76","author":"Casta\u00f1er","year":"2020","journal-title":"J Am Coll Cardiol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1901661\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:33:28Z","timestamp":1788240808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1901661\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":27,"alternative-id":["10.3389\/fcvm.2026.1901661"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1901661","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"1901661"}}